Von Gierke Disease (Type I)

Overview


Plain-Language Overview

Von Gierke Disease (Type I) is a rare inherited disorder that affects the body's ability to manage blood sugar levels. It primarily involves the liver and kidneys, where a specific enzyme deficiency prevents the normal release of glucose into the bloodstream. This leads to dangerously low blood sugar, especially during fasting. People with this condition often experience enlarged liver, growth delays, and episodes of low blood sugar that can cause symptoms like shakiness, sweating, and confusion. The disease is caused by a problem with the body's ability to break down stored sugar, which is essential for energy between meals.

Clinical Definition

Von Gierke Disease (Type I) is a glycogen storage disorder caused by a deficiency of the enzyme glucose-6-phosphatase, which is critical for the final step of gluconeogenesis and glycogenolysis. This enzyme deficiency leads to impaired conversion of glucose-6-phosphate to free glucose, resulting in severe fasting hypoglycemia, hepatomegaly, and renal enlargement due to glycogen accumulation. The condition is inherited in an autosomal recessive pattern, caused by mutations in the G6PC gene. Clinical manifestations include lactic acidosis, hyperuricemia, and hyperlipidemia due to metabolic derangements. The inability to maintain normal blood glucose levels during fasting is the hallmark of this disorder, making it a critical diagnosis in pediatric patients presenting with hypoglycemia and hepatomegaly.

Inciting Event

  • Fasting or prolonged intervals between feeds precipitate hypoglycemia and symptoms.

  • Infections or illnesses that increase metabolic demand can trigger acute metabolic decompensation.

  • Introduction of solid foods or weaning from frequent feeds may unmask symptoms.

Latency Period

  • Symptoms usually appear within the first 3 to 6 months of life after birth as glycogen accumulates and fasting intolerance develops.

  • Diagnosis may be delayed until recurrent hypoglycemia or hepatomegaly becomes clinically apparent.

Diagnostic Delay

  • Initial hypoglycemia may be misattributed to sepsis or other metabolic disorders.

  • Lack of awareness of glycogen storage diseases leads to delayed biochemical testing.

  • Hepatomegaly may be mistaken for infectious or malignant causes.

  • Non-specific symptoms like irritability and poor feeding delay recognition of metabolic etiology.

Clinical Presentation


Signs & Symptoms

  • Severe fasting hypoglycemia causing irritability, seizures, and lethargy is a classic symptom.

  • Doll-like facies with rounded cheeks and thin extremities are characteristic.

  • Abdominal distension from hepatomegaly and nephromegaly is common.

  • Hyperuricemia may cause gout or kidney stones in older patients.

  • Growth delay and delayed puberty are frequent clinical features.

History of Present Illness

  • Recurrent episodes of severe fasting hypoglycemia with symptoms such as irritability, tremors, and seizures.

  • Abdominal distension and hepatomegaly noted by caregivers or on physical exam.

  • Failure to thrive and growth retardation despite adequate caloric intake.

  • Episodes of lactic acidosis and hyperuricemia may present with vomiting and lethargy.

  • Bleeding tendencies due to platelet dysfunction can be reported.

Past Medical History

  • History of frequent hypoglycemic episodes especially during fasting or illness.

  • Previous hospitalizations for seizures or metabolic acidosis without clear etiology.

  • No prior significant illnesses unless related to metabolic complications.

Family History

  • Siblings with similar symptoms or known diagnosis of Von Gierke disease.

  • Consanguineous parents or family members with autosomal recessive disorders.

  • Family history of early childhood hypoglycemia or unexplained hepatomegaly.

Physical Exam Findings

  • Hepatomegaly due to massive glycogen and fat accumulation in the liver is a hallmark finding.

  • Protuberant abdomen from enlarged liver and kidneys is commonly observed.

  • Growth retardation with short stature is frequently noted in affected children.

  • Doll-like facies with rounded cheeks and a thin extremity appearance may be present.

  • Hypoglycemia signs such as pallor, sweating, and lethargy can be observed during fasting.

Diagnostic Workup


Diagnostic Criteria

Diagnosis is established by demonstrating deficient glucose-6-phosphatase activity in liver biopsy tissue or by identifying pathogenic mutations in the G6PC gene through molecular genetic testing. Key clinical findings supporting diagnosis include severe fasting hypoglycemia, hepatomegaly, and characteristic metabolic abnormalities such as lactic acidosis, hyperuricemia, and hyperlipidemia. Imaging may show an enlarged liver and kidneys, but confirmatory diagnosis relies on enzymatic assay or genetic testing.

Pathophysiology


Key Mechanisms

  • Deficiency of glucose-6-phosphatase enzyme impairs the final step of gluconeogenesis and glycogenolysis, preventing glucose release into the bloodstream.

  • Accumulation of glycogen and fat in the liver and kidneys leads to hepatomegaly and nephromegaly.

  • Severe fasting hypoglycemia results from inability to maintain blood glucose during fasting.

  • Increased production of lactate, uric acid, and triglycerides due to shunting of glucose-6-phosphate into alternative metabolic pathways.

  • Metabolic derangements include lactic acidosis, hyperuricemia, and hyperlipidemia caused by disrupted glucose homeostasis.

InvolvementDetails
Organs

Liver is the primary organ involved, exhibiting hepatomegaly, steatosis, and risk of adenomas due to glycogen accumulation.

Kidneys are affected by glycogen deposition causing nephromegaly and potential renal impairment.

Intestines play a role in glucose absorption and are important in dietary management to prevent hypoglycemia.

Tissues

Liver tissue shows massive glycogen and fat accumulation leading to hepatomegaly and dysfunction.

Kidney tissue may develop glycogen accumulation causing nephromegaly and renal dysfunction.

Cells

Hepatocytes are the primary cells affected due to deficient glucose-6-phosphatase activity causing glycogen accumulation.

Neutrophils may be functionally impaired due to metabolic disturbances, increasing infection risk.

Chemical Mediators

Glucose-6-phosphatase deficiency is the fundamental enzymatic defect causing impaired glycogenolysis and gluconeogenesis.

Lactic acid accumulation leads to metabolic acidosis and is a hallmark biochemical abnormality.

Uric acid levels are elevated due to increased nucleotide turnover and impaired renal excretion.

Treatments


Pharmacological Treatments

  • Uncooked cornstarch

    • Mechanism:
      • Provides a slow-release source of glucose to maintain blood sugar levels during fasting.

    • Side effects:
      • Gastrointestinal discomfort

      • Bloating

    • Clinical role:
      • First-line

  • Allopurinol

    • Mechanism:
      • Inhibits xanthine oxidase to reduce hyperuricemia and prevent gout.

    • Side effects:
      • Rash

      • Hepatotoxicity

      • Hypersensitivity reactions

    • Clinical role:
      • Adjunctive

  • Lipid-lowering agents (e.g., fibrates, statins)

    • Mechanism:
      • Reduce hyperlipidemia by decreasing triglyceride and cholesterol synthesis or increasing clearance.

    • Side effects:
      • Myopathy

      • Hepatotoxicity

    • Clinical role:
      • Adjunctive

Non-pharmacological Treatments

  • Frequent oral feeding with high-carbohydrate meals to prevent hypoglycemia.

  • Avoidance of prolonged fasting to maintain stable blood glucose levels.

  • Liver transplantation in severe cases with progressive hepatic adenomas or liver failure.

Prevention


Pharmacological Prevention

  • Allopurinol to prevent gout by lowering uric acid levels.

  • Lipid-lowering agents such as fibrates may be used to manage hypertriglyceridemia.

  • Anticonvulsants may be required to control seizures secondary to hypoglycemia.

Non-pharmacological Prevention

  • Frequent feeding with uncooked cornstarch to maintain normoglycemia and prevent hypoglycemia.

  • Avoidance of prolonged fasting to reduce risk of metabolic crises.

  • Regular monitoring of growth, liver size, and metabolic parameters to detect complications early.

  • Dietary management with a high-protein, low-fat diet to reduce lipid abnormalities.

Outcome & Complications


Complications

  • Severe hypoglycemia can lead to seizures, brain damage, or death if untreated.

  • Hepatic adenomas and risk of hepatocellular carcinoma develop in long-term disease.

  • Renal failure from chronic nephropathy is a serious complication.

  • Lactic acidosis may cause metabolic instability during illness or fasting.

Short-term Sequelae Long-term Sequelae
  • Hypoglycemic seizures and altered mental status during fasting or illness.

  • Lactic acidosis causing nausea, vomiting, and respiratory distress.

  • Hyperlipidemia leading to pancreatitis in acute settings.

  • Hepatic adenomas with potential malignant transformation.

  • Chronic kidney disease progressing to renal failure.

  • Growth retardation and delayed puberty impacting quality of life.

  • Gouty arthritis from persistent hyperuricemia.

Differential Diagnoses


Von Gierke Disease (Type I) versus Pompe Disease (Type II Glycogen Storage Disease)

Von Gierke Disease (Type I)

Pompe Disease (Type II Glycogen Storage Disease)

Autosomal recessive deficiency of glucose-6-phosphatase

Autosomal recessive deficiency of lysosomal acid alpha-glucosidase

Infant or early childhood onset with hepatomegaly and hypoglycemia

Infantile onset with cardiomegaly and muscle weakness

Severe fasting hypoglycemia, lactic acidosis, hyperuricemia, and hyperlipidemia

Elevated creatine kinase and glycogen accumulation in lysosomes

Glycogen accumulation in cytosol of hepatocytes and renal tubular cells

Glycogen accumulation primarily in cardiac and skeletal muscle lysosomes

Von Gierke Disease (Type I) versus Cori Disease (Type III Glycogen Storage Disease)

Von Gierke Disease (Type I)

Cori Disease (Type III Glycogen Storage Disease)

Deficiency of glucose-6-phosphatase

Deficiency of debranching enzyme (amylo-1,6-glucosidase)

Severe fasting hypoglycemia with hepatomegaly and lactic acidosis

Milder hypoglycemia with muscle weakness and cardiomyopathy

Severe hypoglycemia with absent ketones

Mild hypoglycemia with elevated ketone bodies

Von Gierke Disease (Type I) versus Hereditary Fructose Intolerance

Von Gierke Disease (Type I)

Hereditary Fructose Intolerance

Symptoms present regardless of dietary fructose intake

Symptoms triggered by ingestion of fructose-containing foods

Hypoglycemia with elevated lactate and uric acid but normal fructose metabolites

Hypoglycemia with elevated fructose-1-phosphate and phosphate depletion

Deficiency of glucose-6-phosphatase enzyme activity

Deficiency of aldolase B enzyme activity

Von Gierke Disease (Type I) versus McArdle Disease (Type V Glycogen Storage Disease)

Von Gierke Disease (Type I)

McArdle Disease (Type V Glycogen Storage Disease)

Fasting hypoglycemia with hepatomegaly and lactic acidosis

Exercise intolerance with muscle cramps and myoglobinuria

Deficiency of glucose-6-phosphatase

Deficiency of muscle glycogen phosphorylase

Severe fasting hypoglycemia with elevated lactate and uric acid

Elevated creatine kinase and normal blood glucose

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. "USMLE Step 1" and "USMLE Step 2 CK" are used only to identify the relevant examinations.